161 related articles for article (PubMed ID: 23219291)
1. Borderline ovarian tumors: features and controversial aspects.
Messalli EM; Grauso F; Balbi G; Napolitano A; Seguino E; Torella M
Eur J Obstet Gynecol Reprod Biol; 2013 Mar; 167(1):86-9. PubMed ID: 23219291
[TBL] [Abstract][Full Text] [Related]
2. Frozen section in borderline ovarian tumors: is it reliable?
Ureyen I; Turan T; Cirik DA; Tasci T; Boran N; Bulbul D; Tulunay G
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():115-8. PubMed ID: 25145763
[TBL] [Abstract][Full Text] [Related]
3. [Borderline ovarian tumours: a challenge for clinicians].
Nacheva A; Atanasova V; Miloshov V; Ganovska A; Simeonova C
Akush Ginekol (Sofiia); 2013; 52(3):27-30. PubMed ID: 24283059
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
5. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract][Full Text] [Related]
6. Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
Muallem MZ; Parashkevova A; Almuheimid J; Richter R; Diab Y; Braicu EI; Sehouli J
Anticancer Res; 2017 Jun; 37(6):3157-3161. PubMed ID: 28551658
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.
Gungorduk K; Asicioglu O; Braicu EI; Almuheimid J; Gokulu SG; Cetinkaya N; Gungor T; Pakay G; Telli EU; Cuylan ZF; Toptas T; Bilgi A; Ozyurt R; Agacayak E; Ozdemir A; Yildirim N; Taskin S; Oge T; Erol O; Akman L; Turan A; Icen MS; Senol T; Ovali OI; Yucesoy B; Gungorduk O; Temizkan O; Sanci M; Simsek T; Meydanli MM; Harma M; Yasar L; Uysal AD; Karateke A; Ortac F; Ozalp SS; Sehouli J; Muallem MZ
Anticancer Res; 2017 Oct; 37(10):5609-5616. PubMed ID: 28982877
[TBL] [Abstract][Full Text] [Related]
8. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
[TBL] [Abstract][Full Text] [Related]
9. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
12. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
13. Recurrence and prognostic factors in borderline ovarian tumors.
Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
[TBL] [Abstract][Full Text] [Related]
14. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
15. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
16. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
17. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
18. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
19. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
20. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
